ETFs with MDCO as a Top 10 Holding*Sponsored by:
|Weighting||ETF Name (Symbol)||100-Day Price Change (%)|
|3.1%||PowerShares Dynamic Pharmaceuticals (PJP)||+3.46 (9.90%)|
|2.94%||PowerShares Exchange-Traded Fund Trust II PowerShares S&P Smal (PSCH)||+5.62 (15.57%)|
|0.66%||N/A (SGGG)||N/A (N/A)|
|0.59%||WisdomTree SmallCap Earnings Fund (EES)||+4.09 (7.55%)|
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
We are a global biopharmaceutical company focused on saving lives, alleviating suffering and improving the economic efficiency of the world's leading hospitals. We have four marketed products, Angiomax® (bivalirudin), Recothrom® Thrombin, topical (Recombinant), Cleviprex® (clevidipine butyrate) injectable emulsion and our ready-to-use formulation of Argatroban. We also have a pipeline of acute and intensive care hospital products in development, including four late-stage development product candidates, cangrelor, oritavancin, MDCO-157 and IONSYS TM (fentanyl iontophoretic transdermal system), and early stage development product candidates, MDCO-216 and ALN-PCS02 and ALN-PCSsc of our ALN-PCS program. ... More ...